NTLA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Intellia Therapeutics Inc (NTLA) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 to invest. While the company has positive regulatory developments and analyst upgrades, the pre-market price is showing a slight decline (-0.99%), insider selling is significantly high, and financial performance shows declining net income and EPS. Additionally, there are no strong proprietary trading signals to suggest immediate action. The stock may be worth monitoring for future entry points, but it does not currently meet the criteria for a compelling buy.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 44.74, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 12.681, and resistance is at 15.054. The stock is trading below the pivot level of 13.867, suggesting limited upward momentum in the short term.
The FDA has lifted clinical holds on the MAGNITUDE Phase 3 study, which is a significant regulatory milestone. Analysts have responded positively, with multiple upgrades and increased price targets. Revenue increased by 78.79% YoY in Q4 2025.
Insider selling has surged by 2235.78% over the last month, which could indicate a lack of confidence from company insiders. Net income and EPS have both declined significantly YoY. The pre-market price is down 0.99%, and there are no recent proprietary trading signals to suggest immediate upside potential.
In Q4 2025, revenue increased by 78.79% YoY to $23.02M, but net income dropped by 25.69% YoY to -$95.79M, and EPS fell by 34.65% YoY to -$0.83. Gross margin remained stable at 100%. While revenue growth is strong, profitability metrics are deteriorating.
Analysts have shown optimism with multiple upgrades and increased price targets, ranging from $15 to $48. The FDA's lifting of clinical holds has been viewed as a major win, but some analysts remain cautious about safety concerns and market competition.
